National Institute on Alcohol Abuse and Alcoholism (NIAAA) clinical trials
Listed in the registry as: U.S. National Institutes of Health.
The registry lists 102 studies whose lead sponsor is National Institute on Alcohol Abuse and Alcoholism (NIAAA). 15 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the National Institute on Alcohol Abuse and Alcoholism (NIAAA) studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesFocus areas
Conditions National Institute on Alcohol Abuse and Alcoholism (NIAAA) leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 102. Browse all 102 →
- Development Of Neuroimaging Methods To Assess The Neurobiology Of AddictionRecruitingNCT02535702Not applicable
- Role of Metal Ion Transporter ZIP8 in Alcohol-Related BehaviorsRecruitingNCT06819189Phase 1
- Suvorexant for Alcohol Use Disorder (AUD): Neural MechanismsRecruitingNCT06484075Phase 1/2
- Addictions Neuroclinical Assessment (ANA)Enrolling by invitationNCT04946851
- Mechanisms Underlying Individual Variations of Taste and Smell in ObesityRecruitingNCT04714892
- Individual Variations of Taste and Smell Perception in Alcohol Use Disorder (AUD)RecruitingNCT05677321
- Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)RecruitingNCT03407079Phase 2
- Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)RecruitingNCT07559500Phase 1
- Nicotinic Receptor Genetic Variation and Alcohol RewardRecruitingNCT03294460Phase 1
- Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use DisorderRecruitingNCT06269627Phase 4
- NIAAA Natural History ProtocolRecruitingNCT02231840
- Tirzepatide in MetALDRecruitingNCT07046819Phase 2
- Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy DrinkersRecruitingNCT04781322Phase 1
- COVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History StudyRecruitingNCT04391816
- Human Laboratory Study of Apremilast for Alcohol Use DisorderRecruitingNCT07325266Phase 2
- Epi-Genetic Modulators of Fear Extinction in Alcohol DependenceCompletedNCT02438969
- Effect of Acute Alcohol Intoxication on Neural Processes During Decisions to Engage in HIV Risk BehaviorsCompletedNCT04360018Phase 1
- Characterization Imaging Instruments in Alcoholics and Non-AlcoholicsCompletedNCT02108080
- Computer-Assisted Self-Administration of EthanolCompletedNCT00713492Phase 1
- Brain Inflammation and Function in AlcoholismCompletedNCT02233868Early Phase 1
- Title: Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene VariationCompletedNCT02639273Phase 1
- Behavioral and Functional Task Development, Implementation, and TestingCompletedNCT02108054Not applicable
- Human Brain Mapping of the Apparent Diffusion Coefficient (ADC) During Sleep and WakefulnessCompletedNCT02311374Early Phase 1
- Reliability of the Human Brain ConnectomeCompletedNCT02193425Early Phase 1
- Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy PeopleCompletedNCT02669225Early Phase 1
- Brain Dopaminergic Signaling in Opioid Use DisordersCompletedNCT03190954Early Phase 1
- Intranasal Oxytocin for the Treatment of Alcohol Use DisorderCompletedNCT03878316Phase 2
- Human Laboratory Study of ASP8062 for Alcohol Use DisorderCompletedNCT05096117Phase 2
- HLAB-002 of ANS-6637 for Alcohol Use DisorderTerminatedNCT03970109Phase 2
- Ketogenic Diet (KD) in AlcoholismCompletedNCT03255031Not applicable
- Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRICompletedNCT03326245Phase 1
- Study of Structural ImagingCompletedNCT02564991
- Dopamine Rhythms in Health and AddictionWithdrawnNCT02233829Early Phase 1
- A Novel Compound for Alcoholism Treatment: A Translational Strategy - Part IITerminatedNCT02707055Phase 2
- Dietary Essential Fatty Acid Regulation of Omega-3 HUFA Metabolism; Satiety and Body CompositionCompletedNCT01251887Not applicable
- Genetic Effects on Dopamine Response to an OpiateCompletedNCT01878006Phase 2
- Neural Substrates of Approach-Avoidance ConflictCompletedNCT02119624
- National Epidemiologic Survey on Alcohol and Related Conditions-IIICompletedNCT01273220
- The Effect of Ethanol on Brain ActivityCompletedNCT00074360
- A Novel Compound for Alcoholism TreatmentCompletedNCT02039349Phase 1
- The Effect of Positive and Negative Emotions on Brain Activity in Alcoholics and NonalcoholicsCompletedNCT00001675
- Measuring Effects of Alcohol on Brain ChemistryTerminatedNCT01492933
- Genetics of the Acute Response to Alcohol in Social DrinkersTerminatedNCT01375556Phase 1
- Human Laboratory Study of Varenicline for Alcohol Use DisorderCompletedNCT03035708Phase 1/2
- Oxytocin in Alcohol Use DisorderWithdrawnNCT02711189Phase 1
- Study of the Effectiveness of Quetiapine for the Treatment of Alcohol DependencyCompletedNCT00498628Phase 2
- Neuroimaging, Omega-3 and Reward in Adults With ADHD (NORAA) TrialTerminatedNCT02156089Phase 2
- HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use DisorderCompletedNCT02252536Phase 2
- Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy DrinkersCompletedNCT01779024Phase 2
- Alcoholism Assessment and TreatmentCompletedNCT00106093